Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-11
2005-10-11
Barts, Samuel (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06953808
ABSTRACT:
Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H+release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
REFERENCES:
patent: 4758579 (1988-07-01), Kohl et al.
patent: 5888535 (1999-03-01), Gray
patent: 4035455 (1992-05-01), None
Kohl et al. “(H+,K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl) sulfinyl] benzimidazoles . . . ”J. Med. Chem.35, 1049-1057 (1992).
Kromer et al. “BY 1023/SK&F 96033 INN pantoprazole, a Novel Gastric Proton Pump Inhibitor, Potently Inhibits Acid Secretion But Lacks Relevant . . . ”J. Pharm. Exp. Ther.254, 129-135 (1990).
Simon et al. “Single Intravenous Administration of the H+K+-ATPase inhibitor BU 1023/SK&F 96022-inhibition of pentagastrin-stimulated gastric acid . . . ”Aliment. Pharmacol. Therap.4, 239-245 (1990).
Beil et al. “Pantoprazole: a novel H+/K+-ATPase inhibitor with an improved pH stability”Eur. J. Pharm.218 265-271 (1992).
Kromer et al. “Direct Comparison between the Ulcer-Healing Effects of Two H+-K+-ATPase Inhibitors, One M1-Selective Antimuscarinic and One H2Receptor Antagonist in the Rat”Pharmacology41 333-337 (1990).
Larsson et al. “Plasma Gastrin and Gastric Enterochromaffinlike Cell Activation and Proliferation”Gastroenterology90 391-399 (1986).
Decktor et al. “Acute Effects of Ranitidine, Famotidine and Omeprazole on Plasma Gastrin in the Rat”J. Pharm. Exp. Ther.249, 1-5 (1989).
Hannan et al. “Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles”Aliment. Pharmacol. Ther.6 373-380 (1992).
Simon et al. “Effect of repeated oral administration of BY1023/SK&F96022—a new substituted benzimidazole derivative—on pentagastrin-stimulated gastric acid secretion . . . ”Aliment. Pharmacol. Therap.4, 373-379 (1990).
Simon et al. “BY 1023/SK&F 96022: Biochemistry of a Novel (H++K+) ATPase Inhibitor”Biochem. Pharm.39 1799-1806 (1990).
Simon et al. “The H+,K+ATPase Inhibitor Pantoprazole (BY1023/SK&F96022) Interacts with Cytochrome . . . ”Biochem. Pharm.42 347-355 (1991).
Simon et al. “Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following . . . ”Z. Gastroenterol28 443-447 (1990).
Barts Samuel
Sepracor Inc.
LandOfFree
Method for treating gastric disorders using optically pure... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating gastric disorders using optically pure..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating gastric disorders using optically pure... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3436472